Previous evidence have shown that MYCN amplification is one of the critical aspects in tumor progression and poor prognosis in NB, and MYCN is often considered an attractive target for therapeutic intervention strategies in this malignancy [42]–[45]. The gene discussed is MYCN; the disease is neuroblastoma.